To determine the optimal dosage for drug delivery and assess biocompatibility, free ulixertinib was given to control BJ fibroblast cells, WT A375 melanoma cells, and WM3000 metastatic melanoma cells with NRAS mutation at varying concentrations. This evidence concerns the gene NRAS and metastatic melanoma.